Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4698575 | 0.84 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL7842024 | 0.79 | PREP (0.42) | ALDH1A1 | |
| SCHEMBL9655419 | 0.77 | NAAA (0.45) | ALDH1A1 | |
| SCHEMBL13244921 | 0.76 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL18712231 | 0.76 | ALDH1A1 (0.51) | ALDH1A1 | |
| SCHEMBL9655226 | 0.75 | KMT2A (0.48) | — | |
| SCHEMBL9655228 | 0.75 | KMT2A (0.48) | — | |
| SCHEMBL27286630 | 0.75 | ALDH1A1 (0.45) | ALDH1A1 | |
| SCHEMBL4701620 | 0.74 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL13244922 | 0.74 | ALDH1A1 (0.44) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444202-B1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-10-15 | — | — | EP | disclosed |
| US-7132434-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2006-11-07 | — | — | US | disclosed |
| US-20050026990-A1 | Novel metalloproteinase ihibitors | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| EP-1444202-A1 | NOVEL METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040098-A1 | NOVEL METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026990-A1 | Novel metalloproteinase ihibitors | MMP12, MMP1, MMP16 | ALDH1A1 246/4885ROCK2 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.